相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
Hongshan Li et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab
Tomoko Funazo et al.
Journal of Thoracic Oncology (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy
Shu-Lin Yu et al.
SCIENTIFIC REPORTS (2017)
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C. Tumeh et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis
C. Liu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R. Hui et al.
ANNALS OF ONCOLOGY (2017)
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma
M. S. Chatterjee et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer
Sonya C. Tate et al.
EUROPEAN JOURNAL OF CANCER (2016)
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma
Guru Sonpavde et al.
JOURNAL OF UROLOGY (2016)
Mutational signatures associated with tobacco smoking in human cancer
Ludmil B. Alexandrov et al.
SCIENCE (2016)
Prognostic effect of liver metastasis in lung cancer patients with distant metastasis
Yijiu Ren et al.
ONCOTARGET (2016)
The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis
Ilaria Lucca et al.
EUROPEAN UROLOGY FOCUS (2016)
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients
Laurent Claret et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
Valerie F. Cosson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials
R. Bruno et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis
B. Ribba et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2014)
Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy
Andrea B. Apolo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
E. K. Hansson et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer
N. Frances et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Y. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences
A d'Onofrio
PHYSICA D-NONLINEAR PHENOMENA (2005)
分享论文
